PMID- 19086934
OWN - NLM
STAT- MEDLINE
DCOM- 20090224
LR  - 20151119
IS  - 1755-3768 (Electronic)
IS  - 1755-375X (Linking)
VI  - 86
IP  - 8
DP  - 2008 Dec
TI  - Uveal melanoma and macular degeneration: molecular biology and potential 
      therapeutic applications.
PG  - 930-1
LID - 10.1111/j.1755-3768.2008.01188.x [doi]
AB  - Uveal melanoma is the most common primary intraocular malignant tumor in adults 
      with 30% to 50% of patients that ultimately succumb to metastatic disease, mainly 
      to the liver. (Shields et al. 1991) Although new diagnostic and therapeutic tools 
      have been developed during the most recent years, only the eye conservation rate 
      has been achieved, while the survival rate remains poor. The reason for this 
      liver-homing is largely unknown, but it is conceivable that hepatic environmental 
      factors may be implicated in the growth, dissemination, and progression of this 
      malignancy. The insulin-like growth factor (IGF-1) that binds to the IGF-1 
      receptor (IGF-1R) is mainly produced in the liver. It has been shown to be 
      crucial for tumor transformation, maintenance of malignant phenotype, promotion 
      of cell growth, and prevention of apoptosis. (Baserga 1995) The hepatocyte growth 
      factor/scatter factor (HGF/SF) is another growth factor produced in the liver and 
      exerts its biological effects through binding to the plasma membrane receptor 
      c-Met. The activation of this receptor by HGF/SF ligand can induce proliferation, 
      motility, adhesion, and invasion of tumor cells. (Cruz et al. 2003) Metastasis is 
      a process involving many components, including tumor cell adhesion, migration, 
      extracellular matrix (ECM) proteolysis, and invasion. The tumor cells undergo 
      intravasation, disperse via the vascular and the lymphatic systems, and finally 
      extravasate to invade the secondary sites. In all these steps, proteolytic enzyme 
      systems are involved, including the matrix metalloproteinase (MMP) system and the 
      plasminogen activation system. The migration of a malignant cell through the ECM 
      and the basement membrane requires proteolytic activities. (Stetler-Stevenson et 
      al. 1993). Efforts to target the IGF-I system has been made with different types 
      of cancer but not with uveal melanoma.
FAU - Economou, Mario-Alexander
AU  - Economou MA
AD  - Cellular and Molecular Tumour Pathology, Department of Oncology and Pathology, 
      Cancer Center Karolinska, Karolinska Institute, Sweden. 
      mario-alexander.economou@sankterik.se
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Ophthalmol
JT  - Acta ophthalmologica
JID - 101468102
RN  - 0 (Biomarkers)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0F35AOI227 (picropodophyllin)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - L36H50F353 (Podophyllotoxin)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Humans
MH  - Macular Degeneration/*drug therapy
MH  - Melanoma/*drug therapy/*metabolism
MH  - Mice
MH  - Molecular Biology/*methods
MH  - Podophyllotoxin/analogs & derivatives/therapeutic use
MH  - Prognosis
MH  - Receptor, IGF Type 1/antagonists & inhibitors/metabolism
MH  - Signal Transduction
MH  - Uveal Neoplasms/*drug therapy/*metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2008/12/18 09:00
MHDA- 2009/02/25 09:00
CRDT- 2008/12/18 09:00
PHST- 2008/12/18 09:00 [entrez]
PHST- 2008/12/18 09:00 [pubmed]
PHST- 2009/02/25 09:00 [medline]
AID - AOS1188 [pii]
AID - 10.1111/j.1755-3768.2008.01188.x [doi]
PST - ppublish
SO  - Acta Ophthalmol. 2008 Dec;86(8):930-1. doi: 10.1111/j.1755-3768.2008.01188.x.